Clinical Trial Update: A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha [Phase 1]

View source ↗

Summary

Phase 1 study of MOv18 IgE in solid tumors expressing folate receptor alpha is currently recruiting, evaluating safety and early signals of activity in ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MOv18 IgE (MOv18 IgE)

Snippet

Sponsor: Epsilogen Ltd | Conditions: Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 | Status: RECRUITING